CN101584757A - A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy - Google Patents
A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy Download PDFInfo
- Publication number
- CN101584757A CN101584757A CNA2008100976954A CN200810097695A CN101584757A CN 101584757 A CN101584757 A CN 101584757A CN A2008100976954 A CNA2008100976954 A CN A2008100976954A CN 200810097695 A CN200810097695 A CN 200810097695A CN 101584757 A CN101584757 A CN 101584757A
- Authority
- CN
- China
- Prior art keywords
- diabetic nephropathy
- treatment
- chinese medicine
- pharmaceutical composition
- rhizoma coptidis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a kind of Chinese medicine pharmaceutical composition for the treatment of diabetic nephropathy, described compositions is a Ramulus Euonymi 1～3 by weight ratio: Radix Trichosanthis 1～2: Radix Notoginseng 1～2: Rhizoma Coptidis 1～3 is formed.When taking, with the four Chinese medicine pulverize separately, mix, decocting for Chinese herbal medicine method routinely decocts, filters, and takes filtrate.
Description
Technical field
The present invention relates to the Chinese medicine field of medicinal compositions, be specially a kind of diabetic nephropathy drugs compositions that is used for the treatment of, is the Chinese medicine compound prescription with promoting blood circulation and detoxication effect.
Background technology
Diabetic nephropathy is one of topmost microvascular complication of diabetes, also is the main cause that causes chronic renal failure.The early stage clinical manifestation of diabetic nephropathy is for discharging microalbumin in the urine, and symptoms such as azotemia, renal failure late period appears in the clinical albuminuria of the appearance that continues, edema, hypertension.Having data to show that the incidence rate of western countries type 2 diabetes mellitus patient nephropathy is 30%～50%, then is 21.5% in China.Diabetic nephropathy has risen to the first reason into end stagerenaldisease at present, also is the major causes of death of diabetics.
Wide clinical application angiotensin converting enzyme inhibitor treatment diabetic nephropathy, it can reduce albuminuria, delay the deterioration process of diabetes injury of kidney, but side effect such as hyperpotassemia, high serum creatinine are arranged, and it is not effective to all patients.Therefore, searching applied range, the little medicine of side effect remain the emphasis that medical field is paid close attention to.
Among the new method of many treatment diabetic nephropathyes was being studied, the pathogenesis of diabetic nephropathy related to number of ways such as hyperglycemia, hyperlipidemia, whole last saccharifying product, sorbitol, oxygen-derived free radicals, hemorheology, cytokine, signal transduction pathway.Antioxidant vitamin E, inhibitors of protein kinase C, eventually last saccharifying product inhibitor etc. in theory or animal, cell experiment show the effect of certain control diabetic nephropathy, clinical trial is not carried out as yet or is in progress.
Summary of the invention
The traditional Chinese medical science thinks that the pathogenic characteristic of diabetic nephropathy is deficiency in origin and excess in superficiality, simulataneous insufficiency and excessive; Void with kidney,spleen,liver and negative and positive of qi and blood is basis, and wet resistance, blood stasis, expectorant gather for marking.Paying attention to the Chinese medicine compound integrally-regulated, that side effect is little has its original characteristic and advantage in the treatment of diabetic nephropathy, its multicomponent, effect characteristics multi-level, too many levels make the generation probability of untoward reaction reduce greatly.The invention provides a kind of new Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy (being promoting blood circulation and detoxication side), form by a certain percentage by Radix Notoginseng, Rhizoma Coptidis, Ramulus Euonymi, Radix Trichosanthis extract, have effects such as nourishing YIN for benefiting the kidney, heat clearing and damp drying, dissolving blood stasis and detoxication, treating both the principal and the secondary aspects of a disease at the same time, again with promoting blood circulation and detoxication as the crucial rule of treatment.
The Chinese medicine pharmaceutical composition of treatment diabetic nephropathy provided by the invention is made up of Ramulus Euonymi, Radix Trichosanthis, Radix Notoginseng, Rhizoma Coptidis, and each components by weight is a Ramulus Euonymi 1～3: Radix Trichosanthis 1～2: Radix Notoginseng 1～2: Rhizoma Coptidis 1～3.When taking, with the four Chinese medicine pulverize separately, mix, decocting for Chinese herbal medicine method routinely decocts, filters, and takes filtrate.Those skilled in the art know conventional decocting for Chinese herbal medicine method, decoct three times such as but not limited to adding suitable quantity of water, merge decoction liquor.
Promoting blood circulation and detoxication side confirms that in the zoopery in early stage the control diabetic nephropathy is had significant curative effect, and does not have side effect such as high serum creatinine, high blood urea nitrogen.
Promoting blood circulation and detoxication can reach development of diabetic nephropathy, may intervene a plurality of links such as blood sugar lowering, blood fat reducing in the diabetic nephropathy pathogenesis with drug component wherein, improves blood microcirculation, antioxidation is relevant.Kinds of experiments finds that Rhizoma Coptidis, Radix Notoginseng, Ramulus Euonymi, Radix Trichosanthis can blood sugar lowering, and Ramulus Euonymi, Radix Notoginseng, Rhizoma Coptidis help to improve diabetes rat model or patient's lipid metabolic disorder, reduce the content of serum cholesterol, triglyceride, obviously reduce whole blood viscosity, blood plasma viscosity, packed cell volume etc.Berberine, arasaponin, Ramulus Euonymi have antioxidation, remove the function of free radical, and they can protect glutathion and superoxide dismutase, make their activity keep the longer time, remove oxygen-derived free radicals, reduce malonaldehyde, thereby reduce the damage of kidney.
The specific embodiment
Embodiment 1:
Ramulus Euonymi 30g, Radix Trichosanthis 20g, Radix Notoginseng 20g, Rhizoma Coptidis 30g
Embodiment 2
Ramulus Euonymi 20g, Radix Trichosanthis 10g, Radix Notoginseng 10g, Rhizoma Coptidis 20g
Embodiment 3
Ramulus Euonymi 10g, Radix Trichosanthis 10g, Radix Notoginseng 10g, Rhizoma Coptidis 10g
The effective ingredient that four Chinese medicine in the foregoing description is extracted gives 300g left and right sides rat oral gavage.Extracting method: decoct with water three times after Radix Notoginseng, Ramulus Euonymi, Radix Trichosanthis, Rhizoma Coptidis pulverize separately, the mixing, filter, filtrate decompression is condensed into clear paste, continues to be condensed into thick paste, and drying under reduced pressure is pulverized.
Experimental technique: the rat adaptability was fed after 3 days, and STZ lumbar injection 65mg/kg injects measuring blood after 3 days, and the rat of selecting fasting glucose to be higher than 25mmol/L is used rat for experiment.Experiment medicine group is irritated the stomach medicine every day, and positive group is irritated the stomach captopril, and model group is irritated the stomach distilled water.Collect 24h urine with metabolic cage after 10 weeks, measure urinaryalbumin, urine creatine content; Put to death rat, the abdomen cardinal vein is got blood examination and is surveyed blood urea nitrogen, creatinine; The kidney weighing, with the fixing 24h of 10% neutral formalin, the routine paraffin wax embedded section, mesentery territorial matrix area is measured in PAS dyeing.Glomerular filtration rate (GFR)=(urine creatine * urine amount)/serum creatinine.Renal index=two kidney weight/body weight.
Experimental result: the nitrogen matter metabolism after irritating stomach promoting blood circulation and detoxication side of diabetic nephropathy rat significantly improves, and microdose urine protein obviously reduces; In addition, promoting blood circulation and detoxication can make renal index obviously reduce, and nephridial tissue pathology shows that promoting blood circulation and detoxication side's treatment group mesangial region substrate reduces, and the result is as shown in table 1.
Table 1 promoting blood circulation and detoxication side to the influence of diabetic nephropathy kidney of rats function (x ± SD, N=8)
*P＜0.05 is compared in expression with model group
Claims (3)
1, a kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy, it is characterized in that: described compositions is a Ramulus Euonymi 1～3 by weight ratio: Radix Trichosanthis 1～2: Radix Notoginseng 1～2: Rhizoma Coptidis 1～3 is formed.
2, pharmaceutical composition as claimed in claim 1 is characterized in that: the weight ratio of each constituent is a Ramulus Euonymi 3: Radix Trichosanthis 2: Radix Notoginseng 2: Rhizoma Coptidis 3.
3, the purposes of pharmaceutical composition as claimed in claim 1 or 2 in being used for the treatment of diabetic nephropathy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100976954A CN101584757A (en) | 2008-05-23 | 2008-05-23 | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100976954A CN101584757A (en) | 2008-05-23 | 2008-05-23 | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101584757A true CN101584757A (en) | 2009-11-25 |
Family
ID=41369326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100976954A Pending CN101584757A (en) | 2008-05-23 | 2008-05-23 | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101584757A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078397A (en) * | 2011-01-12 | 2011-06-01 | 王伟 | Traditional Chinese medicine compound and preparation method thereof |
| CN102488761A (en) * | 2011-12-31 | 2012-06-13 | 西南大学 | Traditional Chinese medicine composition for treating diabetes, preparation thereof and its preparation method |
| CN102614267A (en) * | 2012-04-24 | 2012-08-01 | 许风国 | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof |
| CN102697909A (en) * | 2012-06-09 | 2012-10-03 | 卞毓平 | Traditional Chinese medicinal composition for treating hyperlipidaemia and diabetes mellitus |
| CN112641880A (en) * | 2020-12-24 | 2021-04-13 | 马玉印 | Traditional Chinese medicine watered pill for treating diabetes and preparation method thereof |
-
2008
- 2008-05-23 CN CNA2008100976954A patent/CN101584757A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102078397A (en) * | 2011-01-12 | 2011-06-01 | 王伟 | Traditional Chinese medicine compound and preparation method thereof |
| CN102078397B (en) * | 2011-01-12 | 2015-04-15 | 王伟 | Traditional Chinese medicine compound and preparation method thereof |
| CN102488761A (en) * | 2011-12-31 | 2012-06-13 | 西南大学 | Traditional Chinese medicine composition for treating diabetes, preparation thereof and its preparation method |
| CN102614267A (en) * | 2012-04-24 | 2012-08-01 | 许风国 | Chinese medicinal composition for treating diabetic nephropathy and preparation method thereof |
| CN102697909A (en) * | 2012-06-09 | 2012-10-03 | 卞毓平 | Traditional Chinese medicinal composition for treating hyperlipidaemia and diabetes mellitus |
| CN112641880A (en) * | 2020-12-24 | 2021-04-13 | 马玉印 | Traditional Chinese medicine watered pill for treating diabetes and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101934030A (en) | Medicinal composition for treating symptom-complex of excessive eating (diabetes) and method for preparing same | |
| Liu et al. | A Chinese medicine formula (Jinqi Jiangtang Tablet): a review on its chemical constituents, quality control, pharmacokinetics studies, pharmacological properties and clinical applications | |
| CN101584757A (en) | A kind of Chinese medicine pharmaceutical composition that is used for the treatment of diabetic nephropathy | |
| Meng et al. | From Xiaoke to diabetes mellitus: a review of the research progress in traditional Chinese medicine for diabetes mellitus treatment | |
| CN103006989B (en) | Medical composition for treating diabetic nephropathy | |
| CN104721467B (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and application thereof | |
| CN106074810A (en) | A kind of three wonderful capsules and preparation method thereof | |
| WO2022242173A1 (en) | Traditional chinese medicine for treatment of diabetic nephropathy | |
| CN107913277A (en) | The purposes of the anti-uric acid nephropathy of tanshinone | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN107648451A (en) | A kind of astragali seu Hedysari Decoction for treating diabetic nephropathy exempts to decoct particle novel form and application thereof | |
| US8747925B2 (en) | Pharmaceutical composition for treating diabetes | |
| CN104042895A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus and use thereof | |
| CN103040983B (en) | Traditional Chinese medicine for preventing and/or treating premonitory apoplexy and preparation method thereof | |
| CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
| CN103830337B (en) | Chinese medicinal composition for treating chronic alcoholic toxic liver disease | |
| CN112451618A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy | |
| CN101269152A (en) | Application of matrimony vine and black fungus in preparing fatty liver resistant medicament | |
| CN107693593B (en) | Traditional Chinese medicine composition for preventing and treating coronary heart disease | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| CN104547910A (en) | Medicine application of Huang'e capsule | |
| US20140037764A1 (en) | Composite of herbal extracts for lowering blood lipid and medication comprising the said composite | |
| CN100525822C (en) | Capsule for treating diabetic nephropathy | |
| CN110368434B (en) | Compound valerian medicine for treating chronic renal failure and its prepn | |
| CN103191225A (en) | Application of hedan preparation in preparation of medicine for preventing and treating lipid disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20091125 |